New treatment for rheumatoid arthritis that doesn't suppress the immune system
Official title: Non-immunosuppressive rheumatoid arthritis DMARD
Funded at Knoubis Bio, INC. · NIH-10761242 · Data updated 2026-11-12
This study is testing a new treatment for rheumatoid arthritis that aims to protect your joints from damage without weakening your immune system, offering hope for those who aren't getting enough relief from current medications.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Knoubis Bio, INC. NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project start | September 21, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $274,414 |
| NIH project number | 1R43AR083327-01 |
| Project ID | NIH-10761242 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who have not achieved sufficient control of their disease with current medications.
✕Less likely to help
Patients who have not been diagnosed with rheumatoid arthritis or those who are already well-controlled on existing therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel biologic therapy for rheumatoid arthritis (RA) that targets specific cells in the joints responsible for joint damage, without suppressing the immune system. The approach aims to reduce the migration and invasion of fibroblast-like synoviocytes, which play a significant role in the progression of RA. By demonstrating the effectiveness of this treatment in preclinical models, the researchers hope to provide a new option for patients who do not achieve adequate control with existing medications. If successful, this therapy could be used alone or alongside current treatments to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for rheumatoid arthritis patients that does not compromise their immune system.
How similar studies have gone: While the approach of targeting fibroblast-like synoviocytes is innovative, similar strategies in developing non-immunosuppressive therapies for RA have shown promise in preliminary studies.
Where this research is happening
-
Knoubis Bio, INC.
San Diego, United States Active
Researchers
- Principal investigator: Stanford, Stephanie — Knoubis Bio, INC.
- Study coordinator: Stanford, Stephanie
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Role of Stabilin receptors in rheumatoid arthritis
A short study to understand how certain scavenger receptors may influence the development and progression of rheumatoid arthritis in adults.
-
IgG glycosylation and endothelial FcγRIIB: understanding RA-related heart and blood vessel disease
This project looks at how rheumatoid arthritis affects blood vessels and clotting, with the goal of uncovering new ways to prevent heart and stroke risk for people with RA.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Pregnancy changes in rheumatoid arthritis and new treatment ideas
This research seeks to understand why some women’s rheumatoid arthritis improves during pregnancy and how to predict and mimic that effect to make treatments safer and more effective for pregnant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.